Patent disputes haven't materialized in the RNAi field yet, but once products near the market, it might be a different story. Charlie Schmidt investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Angrist, M. & Cook-Deegan, R.M. The New Atlantis 11, 87–96 (2006).
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Silent running: the race to the clinic
Safety concerns raised over RNA interference
RNA therapy tackles eye disease
Web links
Rights and permissions
About this article
Cite this article
Schmidt, C. Negotiating the RNAi patent thicket. Nat Biotechnol 25, 273–275 (2007). https://doi.org/10.1038/nbt0307-273
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0307-273
This article is cited by
-
Pledging Patent Rights for Fighting Against the COVID-19: From the Ethical and Efficiency Perspective
Journal of Business Ethics (2022)
-
Alienation from the Objectives of the Patent System: How to Remedy the Situation of Biotechnology Patent
Science and Engineering Ethics (2019)
-
The intellectual property landscape for gene suppression technologies in plants
Nature Biotechnology (2010)
-
Patenting and licensing in genetic testing: ethical, legal and social issues
European Journal of Human Genetics (2008)
-
MicroRNA gets down to business
Nature Biotechnology (2007)